Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Summary

This pilot clinical trial studies magnetic resonance (MRI)-guided focal stereotactic radiosurgery (SRS) in treating patients with low- or intermediate-risk localized prostate cancer. Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Conditions

• Adenocarcinoma of the Prostate
• Recurrent Prostate Cancer
• Stage I Prostate Cancer
• Stage IIA Prostate Cancer
• Stage IIB Prostate Cancer

Interventions

RADIATION

stereotactic radiosurgery

Undergo MRI-guided focal SRS

DEVICE

magnetic resonance imaging

Undergo staging MRI with contrast

OTHER

quality-of-life assessment

Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time

PROCEDURE

Serum Prostate Antigen Test

Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.

PROCEDURE

Digital Rectal Exam

Exam of rectal health. Performed every three months for up to two years throughout the study.

BEHAVIORAL

Expanded Prostate Cancer Index Composite

This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.

Sponsors & Collaborators

• Case Comprehensive Cancer Center

  lead OTHER

Principal Investigators

• Elisha Fredman, MD · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

MALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-02-16

Primary Completion

2021-07-28

Completion

2021-07-28

Countries

• United States

Study Locations